Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
8
Radioimmunotherapy of Melanoma with Novel LGG to Melanin
Award last edited on: 10/25/2017
Sponsored Program
SBIR
Awarding Agency
NIH : NIMHD
Total Award Amount
$295,782
Award Phase
1
Solicitation Topic Code
NCI
Principal Investigator
Linda Park
Company Information
Rad Immune Inc
1325 Howard Avenue Suite #919
Burlingame, CA 94010
(310) 650-5986
inquiry@radimmune.com
radimmune.com/
Location:
Single
Congr. District:
33
County:
Los Angeles
Phase I
Contract Number:
----------
Start Date:
----
Completed:
----
Phase I year
2016
Phase I Amount
$295,782
In spite of several novel drugs for metastatic melanoma entering the market in the last few years there is an enormous need for novel effective treatments that would not rely on patients specific genotypes biochemical pathways or the variability of an individual s immune response Previously we conducted a successful Phase clinical trial of an antibody to melanin radiolabeled with beta emitter Rhenium However the IgM isotype of that antibody presented an impediment to further clinical development Recently we have identified a novel antibody to melanin with the IgG isotype which can be easily humanized for future clinical trials The long term goal of the proposal is to develop and bring to the market the radioimmunotherapy of metastatic melanoma based on this novel IgG to melanin We are planning the following Aims Perform the conjugation of C IgG with the chelating agents to enable radiolabeling with alpha and beta emitting therapeutic radionuclides Carry out pharmacokinetics pharmacodynamics studies of radiolabeled C in murine and human melanoma models Use the data from these studies to perform radiation dosimetry calculations Perform proof of concept RIT experiments in murine and human melanoma models Assess the efficacy and short term toxicity of the treatment We anticipate that both beta and alpha emitting radionuclide radiolabeled IgG to melanin will be effective in slowing down or abrogating experimental tumor growth and also safe towards all major organs Based on the realistic estimates of radionuclides commercial availability we will make the selection of the most suitable radiolabeled form of IgG to melanin for the future IND enabling experiments
Phase II
Contract Number:
----------
Start Date:
----
Completed:
----
Phase II year
----
Phase II Amount
----
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.